Neuroprotective Effects of a Novel Non–Receptor-Binding Estrogen Analogue
- 1 October 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 33 (10) , 2485-2491
- https://doi.org/10.1161/01.str.0000030317.43597.c8
Abstract
Background and Purpose— Although estrogens are neuroprotective, hormonal effects limit their clinical application. Estrogen analogues with neuroprotective function but lacking hormonal properties would be more attractive. The present study was undertaken to determine the neuroprotective effects of a novel 2-adamantyl estrogen analogue, ZYC3. Methods— Cytotoxicity was induced in HT-22 cells by 10 mmol/L glutamate. 17β-Estradiol (E2) or ZYC3 was added immediately before the exposure to glutamate. Cell viability was determined by calcein assay. The binding of E2 and ZYC3 to human α (ERα) and β (ERβ) estrogen receptors was determined by ligand competition binding assay. Ischemia/reperfusion injury was induced by temporary middle cerebral artery occlusion (MCAO). E2 or ZYC3 (100 μg/kg) was administered 2 hours or immediately before MCAO, respectively. Infarct volume was determined by 2,3,5-triphenyltetrazolium chloride staining. Cerebral blood flow was recorded during and within 30 minutes after MCAO by a hydrogen clearance method. Results— ZYC3 significantly decreased toxicity of glutamate with a potency 10-fold that of E2. ZYC3 did not bind to either ERα or ERβ. Infarct volume was significantly reduced to 122.4±17.6 and 83.1±19.3 mm 3 in E2 and ZYC3 groups, respectively, compared with 252.6±15.6 mm 3 in the ovariectomized group. During MCAO, both E2 and ZYC3 significantly increased cerebral blood flow in the nonischemic side, while no significant differences were found in the ischemic side. However, E2 and ZYC3 significantly increased cerebral blood flow in both sides within 30 minutes after reperfusion. Conclusions— Our study shows that ZYC3, a non–receptor-binding estrogen analogue, possesses both neuroprotective and vasoactive effects, which offers the possibility of clinical application for stroke without the side effects of estrogens. It also suggests that both the neuroprotective and vasoactive effects of estrogen are receptor independent.Keywords
This publication has 35 references indexed in Scilit:
- A Clinical Trial of Estrogen-Replacement Therapy after Ischemic StrokeNew England Journal of Medicine, 2001
- Estrogen protects against ??-amyloid-induced neurotoxicity in rat hippocampal neurons by activation of AktNeuroReport, 2001
- 17-β Estradiol Can Reduce Secondary Ischemic Damage and Mortality of Subarachnoid HemorrhageJournal of Cerebral Blood Flow & Metabolism, 2001
- Neuroprotection by estradiolProgress in Neurobiology, 2001
- Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neuronsJournal of Neuroscience Research, 2000
- Estrogen as a Neuroprotectant in StrokeJournal of Cerebral Blood Flow & Metabolism, 2000
- 17β-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptorsBrain Research, 1997
- Postischemic Cerebral Blood Flow Recovery in the Female: Effect of 17β-EstradiolJournal of Cerebral Blood Flow & Metabolism, 1995
- Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactionsJournal of Chemical Information and Computer Sciences, 1987
- The adamantyl carbonium ion as a dehydrogenating agent, its reactions with estroneTetrahedron, 1968